Immunovant Inc
(NAS:IMVT)
$
30.92
0.41 (1.34%)
Market Cap: 4.52 Bil
Enterprise Value: 3.82 Bil
PE Ratio: 0
PB Ratio: 7.29
GF Score: 39/100 Immunovant Inc (IMVT) Transcripts
- Immunovant Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Immunovant Inc To Discuss Portfolio Update Call TranscriptNov 28, 2023
- Immunovant Inc Initial Phase 1 Results Call TranscriptSep 26, 2023
- Immunovant Inc Fireside Chat Hosted by LifeSci Capital TranscriptDec 08, 2022
- Immunovant Inc Investor Day TranscriptSep 28, 2022
- Immunovant Inc To Discuss On Two New Indications For Batoclimab Call TranscriptSep 07, 2022
- Q4 2022 Immunovant Inc Earnings Call TranscriptJun 08, 2022$3.92 (-8.20%)Earnings
- Immunovant Inc at UBS Global Healthcare Conference TranscriptMay 23, 2022
- Immunovant Inc To Host R&D Day (Virtual) TranscriptMar 30, 2022
- Immunovant Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call TranscriptJan 05, 2022
- Immunovant Inc at Stifel Healthcare Conference (Virtual) TranscriptNov 17, 2021
- Immunovant Inc at Roivant R&D Day (Virtual) TranscriptSep 28, 2021
- Q1 2022 Immunovant Inc Earnings Call TranscriptAug 09, 2021$7.78 (+0.39%)Earnings
- Q4 2021 Immunovant Inc Earnings Call TranscriptJun 01, 2021$9.4 (-37.99%)Earnings
- Immunovant, Inc. - Special Call TranscriptFeb 02, 2021
- Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 12, 2020
- Immunovant, Inc. - Special Call TranscriptAug 25, 2020
- Immunovant Inc Annual Shareholders Meeting TranscriptAug 19, 2020
- Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update TranscriptMar 30, 2020
- 1